Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus
- PMID: 26311716
- DOI: 10.1136/gutjnl-2014-308865
Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus
Abstract
Background: The effectiveness of surveillance endoscopy in patients with Barrett's oesophagus (BE) for reducing oesophageal adenocarcinoma (EAC)-related mortality in patients with BE is unclear.
Methods: This is a cohort study of patients with BE diagnosed in the National Veterans Affairs hospitals during 2004-2009 excluding those with conditions that affect overall survival. We identified those diagnosed with EAC after BE diagnosis through 2011 and conducted chart reviews to identify BE surveillance programme, and indication for EAC diagnosis, verify diagnosis, stage, therapy and cause of death. We examined the association between surveillance indication for EAC diagnosis with or without surveillance programme and EAC stage and treatment receipt in logistic regression models, and with time to death or cancer-related death using a Cox proportional hazards regression model.
Results: Among 29 536 patients with BE, 424 patients developed EAC during a mean follow-up of 5.0 years. A total of 209 (49.3%) patients with EAC were in BE surveillance programme and were diagnosed as a result of surveillance endoscopy. These patients were more likely to be diagnosed at an early stage (stage 0 or 1: 74.7% vs 56.2, p<0.001), survived longer (median 3.2 vs 2.3 years; p<0.001) and have lower cancer-related mortality (34.0% vs 54.0%, p<0.0001) and had a trend to receive oesophagectomy (51.2% vs 42.3%; p=0.07) than 215 patients diagnosed by non-BE surveillance endoscopy (17.2% of whom were BE surveillance failure). BE surveillance endoscopy was associated with a decreased risk of cancer-related death (HR 0.47, 0.35 to 0.64), which was largely explained by the early stage of EAC at the time of diagnosis. Similarly, the adjusted mortality for patients with cancer in a prior surveillance programme for overall death was 0.63 (0.47 to 0.84) compared with patients with cancer not in a surveillance programme.
Conclusions: Surveillance endoscopy among patients with BE is associated with significantly better EAC outcomes including cancer-related mortality compared with other non-surveillance endoscopy.
Keywords: DECISION ANALYSIS; HEALTH SERVICE RESEARCH.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.Am J Gastroenterol. 2014 Aug;109(8):1215-22. doi: 10.1038/ajg.2014.156. Epub 2014 Jul 1. Am J Gastroenterol. 2014. PMID: 24980881
-
Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?Endoscopy. 2006 Feb;38(2):162-9. doi: 10.1055/s-2005-921184. Endoscopy. 2006. PMID: 16479424
-
The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.Am J Gastroenterol. 2017 Jul;112(7):1049-1055. doi: 10.1038/ajg.2017.18. Epub 2017 Feb 28. Am J Gastroenterol. 2017. PMID: 28244499
-
Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?Dig Dis Sci. 2018 Aug;63(8):2081-2093. doi: 10.1007/s10620-018-5065-9. Dig Dis Sci. 2018. PMID: 29713986 Review.
-
Should patients with Barrett's oesophagus be kept under surveillance? The case for.Best Pract Res Clin Gastroenterol. 2008;22(4):721-39. doi: 10.1016/j.bpg.2008.03.002. Best Pract Res Clin Gastroenterol. 2008. PMID: 18656826 Review.
Cited by
-
Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma.Sci Rep. 2019 Mar 26;9(1):5168. doi: 10.1038/s41598-019-41490-w. Sci Rep. 2019. PMID: 30914682 Free PMC article.
-
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinoma.Gut. 2024 May 10;73(6):897-909. doi: 10.1136/gutjnl-2023-331557. Gut. 2024. PMID: 38553042 Free PMC article.
-
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.Lancet. 2020 Aug 1;396(10247):333-344. doi: 10.1016/S0140-6736(20)31099-0. Lancet. 2020. PMID: 32738955 Free PMC article. Clinical Trial.
-
Receipt of Serial Endoscopy Procedures Prior to Esophageal Adenocarcinoma Diagnosis Is Associated with Better Survival.Dig Dis Sci. 2022 Mar;67(3):1036-1044. doi: 10.1007/s10620-021-06927-1. Epub 2021 Apr 21. Dig Dis Sci. 2022. PMID: 33881677 Free PMC article.
-
Prognostic, Diagnostic and Predictive Biomarkers in the Barrett's Oesophagus-Adenocarcinoma Disease Sequence.Cancers (Basel). 2022 Jul 14;14(14):3427. doi: 10.3390/cancers14143427. Cancers (Basel). 2022. PMID: 35884487 Free PMC article. Review.
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical